CHARITY REGISTRATION NUMBER: 1155193

Nottinghamshire Leukaemia Appeal

Financial Statements

31 December 2025

Nottinghamshire Leukaemia Appeal

Financial Statements

Year ended 31 December 2025

	Page
Trustees' annual report	1
Independent examiner's report to the trustees	4
Statement of financial activities	5
Statement of financial position	6
Notes to the financial statements	7

Nottinghamshire Leukaemia Appeal

Trustees' Annual Report

Year ended 31 December 2025

The trustees present their report and the unaudited financial statements of the charity for the year ended 31 December 2025.

Reference and administrative details

Registered charity name	Nottinghamshire Leukaemia Appeal
Charity registration number	1155193
Principal office	Biodiscovery Institute-room B209 University Park Nottingham NG7 2RD

Trustees

Mr G K Abbott
Mrs M S Stoakes
Dr. M J Pallis

Independent examiner

Governing Document

The Nottinghamshire Leukaemia Appeal also known as NLA is a charity which is an unincorporated trust governed by the Trust Deed dated 5th November 2013.

Organisational Structure

Trustees meet quarterly with other members of the committee. Quarterly meetings are normally held to review fund raising activities being undertaken by supporters of the NLA and to consider applications for funding of research or patient welfare.

Trustees are selected on the basis of their experience and the benefits which they can bring to the charity. Other members are invited to join the committee based upon their knowledge and experience. The committee includes members who have relevant scientific medical knowledge required to assess research applications.

Objectives and activities

The purposes of the charity are to promote the advancement of the treatment of leukaemia and blood cancers by supporting research at Nottingham University hospitals and to promote the treatment, care and welfare of patients with leukaemia and blood cancers at Nottingham University hospitals.

Nottinghamshire Leukaemia Appeal

Trustees' Annual Report

Year ended 31 December 2025

Achievements and performance

Income

Income is generated from donations and promoting sponsored events.

The Trustees are very grateful to supporters of the charity in continuing to raise funds and to members of the public who have made donations.

Support

Nottingham University Department of Haematology has an established ethically approved bank of cells, DNA and RNA. The NLA provide £13,500 each year to make it possible to process samples from new patients, to separate and freeze their cells to make DNA and RNA and to keep alive stocks of blood cancer cell lines. This resource is essential for the success of research and has resulted in four peer-reviewed journal articles from the group in the past five years, with a further publication under review and others in preparation.

- Grundy M, Lucken K, Xing X, Simpson EL, Worker A, Bayyoomi A, Beckett AJ, Prior IA, Booth DG, Seedhouse CH. Abnormal nucleoli architecture and aggregate formation in nucleophosmin mutated acute myeloid leukaemia. Paper under review with Journal Cell Science
- James JR, Curd J, Ashworth JC, Abuhantash M, Grundy M, Seedhouse CH, Arkill KP, Wright AJ, Merry CLR, Thompson A. Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML. Int J Mol Sci. 2023;24(4):4235
- Bailey GD, Doolan L, Baskar A, Smith LC, Seedhouse CH. Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia. Scientific Reports 2020 10(1) 17695
- Grundy M, Al-Kaisi F, Cull J, Williams C, Smith D, Seedhouse CH. A same day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3 mimetic targeting in multiple myeloma cells. EJHaem 2020
- Alhuthali HM, Bradshaw TD, Lim KH, Tam KS, Seedhouse CH. The natural alkaloid Jerantinine B has activity in acute myeloid leukaemia cells through a mechanism involving c-Jun. BMC Cancer 2020 20(1) 629.

Funding for the salary of Dr Martin Grundy is in place. Dr Grundy is in charge of collection and processing patient samples and has a wealth of experience in this technically challenging area (blood/bone marrow cells are incredibly fragile and notoriously difficult to work with to generate meaningful results). Research projects he is involved in include testing new genetic agents in leukaemia and assessing exactly what occurs in leukaemia cells as they proliferate and how this differs to normal healthy blood cells. He has also been involved in developing models for leukaemia and myeloma to best replicate what happens in a patient. In addition, Dr Grundy is working on the role of the mutated nucleophosmin protein in leukaemia and has been using special imaging equipment to study what happens in real time in leukaemia cells as they grow and divide. He has found abnormalities in leukaemia cells harbouring the mutated protein. These results have been submitted for publication in the Journal of Cell Science and the manuscript is currently under expert review. The work is continuing to identify how we might specifically target and kill the mutant cells without affecting the normal blood cells.

The NLA are also funding Dr Alexander Kondrashov for five months. Dr Kondrashov is developing novel genetic models to recreate leukaemia initiating events. This involves growing leukaemia cells from patients in special culture to allow the production and manipulations of stem cell – these are the cells that start the leukaemia. The aim is to develop a novel model of early onset leukaemia.

The work supported fulfils the objective of the NLA to promote the advancement of research into the treatment of leukaemia in Nottinghamshire. The quality of the funded research is evident by publication in international peer-reviewed journals (three articles published in 2018, one in 2019, three in 2020, one

in 2023, one under review 2024 and several others in preparation).

Research updates and outputs are regularly featured on the NLA website to ensure our supporters are aware of the research work being funded.

Financial review

Donations and legacies received were £6,824 (2024: £3,624).

Fund raising events generated net income of £31,955 (2024: £34,217).

Running costs were kept to a minimum at £947 (2024: £710).

No payments (2024: Nil) or other benefits were made to trustees and committee members.

Awards and donations made were £15,500 (2024: £60,548).

Unrestricted reserves were £69,295 (2024: £42,810).

The trustees' annual report was approved on 14th September 2026 signed on behalf of the board of trustees by:

G K Abbott

Mr G K Abbott
Trustee

Nottinghamshire Leukaemia Appeal

Independent Examiner's Report to the Trustees of Nottinghamshire Leukaemia Appeal

Year ended 31 December 2025

I report to the trustees on my examination of the financial statements of Nottinghamshire Leukaemia Appeal ('the charity') for the year ended 31 December 2025.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or

2. the financial statements do not accord with those records;

3. the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

K A Anderson

Mr K A Anderson

Independent Examiner

15th October 2026

Nottinghamshire Leukaemia Appeal

Statement of Financial Activities

Year ended 31 December 2025

	Note	2025 Unrestricted funds	2025 Total funds	2024 Total funds
		£	£	£
Incoming Resources				
Income and endowments				
Donations and legacies	**4**	8,564	8,564	3,624
Funding raising activities	**5**	33,695	33,695	35,917
Investment income	**6**	2,373	2,373	2,653
Total income		44,632	44,632	42,194
Resources Expended				
Costs				
Costs of fund-raising activities	**7**	1,700	1,700	1,700
Charitable donations and other costs	**8,9**	16,447	16,447	61,258
Total Outgoings		18,147	18,147	62,958
Net Surplus/(deficit)		26,485	26.845	(20,764)
Reconciliation of funds				
Total funds brought forward		42,810	42,810	62,574
Total funds carried forward		69,295	69,295	42,810

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure is derive from continuing activities.

Nottinghamshire Leukaemia Appeal

Statement of Financial Position

31 December 2025

	Note	2025 £	2024 £
Current Assets			
Cash at bank and in hand		182,949	222,736
Debtors		239	-
Total current assets		183,188	222,736
Creditors: amounts falling due within one year	10	98,013	139,737
Net Current Assets		**85,175**	82,299
Creditors: **amounts falling due after one year**	**10**	15,880	40,189
Total Net Assets		**69,295**	**42,810**
Funds of the charity			
Unrestricted funds		69,295	42,810
Total charity funds		**69,295**	**42,810**

These financial statements were approved by the board of trustees and authorised for issue on 14th September 2026, and are signed on behalf of the board by:

G K Abbott

Mr G K Abbott
Trustee

1. General information

The charity is a public benefit entity and a registered charity in England and Wales and is unincorporated. The address of the principal office is Biodiscovery Institute-room B209 University Park ,Nottingham, NG7 2RD.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Charities Act 2011.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income:

- income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably.

- legacy income is recognised when receipt is probable and entitlement is established.

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates:

- expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods.

- expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those

support costs and costs relating to the governance of the charity apportioned to charitable activities.

- other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

4. Donations and legacies

	Total Funds 2025	Total Funds 2024
	£	£
Donations		
Donations and Legacies	8,564	3,624

5. Fund raising activities

	Total Funds 2025	Total Funds 2024
	£	£
Fundraising activities	33,695	35,917

6. Investment income

	Total Funds 2025	Total Funds 2024
	£	£
Bank interest receivable	2,373	2,653

Costs of fundraising activities

	Total Funds 2025	Total Funds 2024
	£	£
Fund raising costs	1,700	1,700

8. Expenditure on charitable activities

	Total Funds 2025	Total Funds 2024
	£	£
Charity donations and support	15,500	60.548
Administration and support costs	947	710
	16,447	61,258

9. Trustee remuneration and expenses

No remuneration or other benefits were received by the trustees.

10. Creditors

Creditors include committed support on 31 December 2025 of £113,893 (2024: £179,926) of which £ 15,880 (2024: £40,189) is due after more than one year.